D Le1,2, M Eslami2, H Li3, O Hajjaj1,2,3,4, S Chia2,4, C Simmons2,4. 1. BC Cancer, Fraser Valley Cancer Centre, Surrey, BC. 2. University of British Columbia, Vancouver, BC. 3. Yale School of Public Health, New Haven, CT, U.S.A. 4. BC Cancer, Vancouver Centre, Vancouver, BC.
Abstract
Background: Studies in the adjuvant setting suggest that the timing of breast cancer diagnosis, surgery, and chemotherapy might affect outcomes. In the neoadjuvant setting, data exploring whether expeditious neoadjuvant chemotherapy (nac) after diagnosis improves the rate of pathologic complete response (pcr) in breast cancer are limited. Methods: Patients who received nac and completed treatment between May 2012 and December 2018 were identified from a prospectively collected database at BC Cancer. Time from diagnosis to start of nac was calculated. Patients were grouped into those who did and did not experience a pcr, and those who started nac within 28 days or after 28 days [time to nac (ttn)]. The association between pcr and ttn was tested using logistic regression. Results: In the time period studied, 482 patients who received nac were identified. After exclusions, 421 patients met the eligibility criteria. Median time from biopsy to chemotherapy was 33 days (range: 7-140 days). In 149 patients (35.4%), nac was received within 28 days of diagnosis (range: 7-28 days); in 272 patients (64.6%), it was received after more than 28 days (range: 29-140 days). The overall pcr rate was 31.8%. A trend toward a higher pcr rate, although not statistically significant, was observed in the group that initiated chemotherapy within 28 days (34.2% vs. 30.5%, p = 0.43). In the logistic regression model, rates of pcr were associated with receptor status, but not age, stage, or ttn. Conclusions: In the neoadjuvant setting, we observed no difference in the rate of pcr in patients who started nac within 28 days or after 28 days. 2020 Multimed Inc.
Background: Studies in the adjuvant setting suggest that the timing of breast cancer diagnosis, surgery, and chemotherapy might affect outcomes. In the neoadjuvant setting, data exploring whether expeditious neoadjuvant chemotherapy (nac) after diagnosis improves the rate of pathologic complete response (pcr) in breast cancer are limited. Methods:Patients who received nac and completed treatment between May 2012 and December 2018 were identified from a prospectively collected database at BC Cancer. Time from diagnosis to start of nac was calculated. Patients were grouped into those who did and did not experience a pcr, and those who started nac within 28 days or after 28 days [time to nac (ttn)]. The association between pcr and ttn was tested using logistic regression. Results: In the time period studied, 482 patients who received nac were identified. After exclusions, 421 patients met the eligibility criteria. Median time from biopsy to chemotherapy was 33 days (range: 7-140 days). In 149 patients (35.4%), nac was received within 28 days of diagnosis (range: 7-28 days); in 272 patients (64.6%), it was received after more than 28 days (range: 29-140 days). The overall pcr rate was 31.8%. A trend toward a higher pcr rate, although not statistically significant, was observed in the group that initiated chemotherapy within 28 days (34.2% vs. 30.5%, p = 0.43). In the logistic regression model, rates of pcr were associated with receptor status, but not age, stage, or ttn. Conclusions: In the neoadjuvant setting, we observed no difference in the rate of pcr in patients who started nac within 28 days or after 28 days. 2020 Multimed Inc.
Entities:
Keywords:
Breast cancer; neoadjuvant chemotherapy; pathologic complete response; time to treatment
Authors: Elizabeth A Mittendorf; Thomas A Buchholz; Susan L Tucker; Funda Meric-Bernstam; Henry M Kuerer; Ana M Gonzalez-Angulo; Isabelle Bedrosian; Gildy V Babiera; Karen Hoffman; Min Yi; Merrick I Ross; Gabriel N Hortobagyi; Kelly K Hunt Journal: Ann Surg Date: 2013-02 Impact factor: 12.969
Authors: Patricia Cortazar; Lijun Zhang; Michael Untch; Keyur Mehta; Joseph P Costantino; Norman Wolmark; Hervé Bonnefoi; David Cameron; Luca Gianni; Pinuccia Valagussa; Sandra M Swain; Tatiana Prowell; Sibylle Loibl; D Lawrence Wickerham; Jan Bogaerts; Jose Baselga; Charles Perou; Gideon Blumenthal; Jens Blohmer; Eleftherios P Mamounas; Jonas Bergh; Vladimir Semiglazov; Robert Justice; Holger Eidtmann; Soonmyung Paik; Martine Piccart; Rajeshwari Sridhara; Peter A Fasching; Leen Slaets; Shenghui Tang; Bernd Gerber; Charles E Geyer; Richard Pazdur; Nina Ditsch; Priya Rastogi; Wolfgang Eiermann; Gunter von Minckwitz Journal: Lancet Date: 2014-02-14 Impact factor: 79.321
Authors: Richard J Bleicher; Karen Ruth; Elin R Sigurdson; J Robert Beck; Eric Ross; Yu-Ning Wong; Sameer A Patel; Marcia Boraas; Eric I Chang; Neal S Topham; Brian L Egleston Journal: JAMA Oncol Date: 2016-03 Impact factor: 31.777
Authors: Debora de Melo Gagliato; Ana M Gonzalez-Angulo; Xiudong Lei; Richard L Theriault; Sharon H Giordano; Vicente Valero; Gabriel N Hortobagyi; Mariana Chavez-Macgregor Journal: J Clin Oncol Date: 2014-01-27 Impact factor: 44.544
Authors: Louise Eriksson; Jonas Bergh; Keith Humphreys; Fredrik Wärnberg; Sven Törnberg; Kamila Czene Journal: Int J Cancer Date: 2018-04-17 Impact factor: 7.396
Authors: Gunter von Minckwitz; Chiun-Sheng Huang; Max S Mano; Sibylle Loibl; Eleftherios P Mamounas; Michael Untch; Norman Wolmark; Priya Rastogi; Andreas Schneeweiss; Andres Redondo; Hans H Fischer; William Jacot; Alison K Conlin; Claudia Arce-Salinas; Irene L Wapnir; Christian Jackisch; Michael P DiGiovanna; Peter A Fasching; John P Crown; Pia Wülfing; Zhimin Shao; Elena Rota Caremoli; Haiyan Wu; Lisa H Lam; David Tesarowski; Melanie Smitt; Hannah Douthwaite; Stina M Singel; Charles E Geyer Journal: N Engl J Med Date: 2018-12-05 Impact factor: 176.079